Josh Schimmer Analyst Performance

Biotech Equity Research Analyst at Cantor Fitzgerald

Josh Schimmer is a stock analyst at Cantor Fitzgerald, covering 17 publicly traded companies across a range of sectors. Over the past year, Josh Schimmer has issued 15 stock ratings, including buy and hold recommendations. While full access to Josh Schimmer's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Josh Schimmer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 20 Last 8 Years
Buy Recommendations: 95.00% 19 Buy Ratings
Companies Covered: 17 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	95.0%	19 ratings
Hold	5.0%	1 ratings
Sell	0.0%	0 ratings

Out of 20 total stock ratings issued by Josh Schimmer at Cantor Fitzgerald, the majority (95.0%) have been Buy recommendations, followed by 5.0% Hold.

Best & Worst Calls

Best Call
000.0%
ICVX
Jun 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
SPRO
Sep 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	17 companies

Josh Schimmer, an analyst at Cantor Fitzgerald, currently covers 17 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 17 companies	100.0%

Josh Schimmer of Cantor Fitzgerald specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 13 companies	76.5%
BIOTECHNOLOGY 2 companies	11.8%
MED - GENERIC DRG 1 company	5.9%
MEDICAL SERVICES 1 company	5.9%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
CGON CG Oncology	9/8/2025	Reiterated Rating	$32.81	$75.00	Overweight
DNLI Denali Therapeutics	9/8/2025	Reiterated Rating	$15.37		Overweight
SEPN Septerna	9/5/2025	Reiterated Rating	$14.44	$25.00	Overweight
CABA Cabaletta Bio	9/5/2025	Reiterated Rating	$1.61	$15.00	Overweight
RCKT Rocket Pharmaceuticals	8/8/2025	Lower Price Target	$2.90	$8.00	Overweight
BBIO BridgeBio Pharma	7/29/2025	Reiterated Rating	$46.59	$95.00	Overweight
TRVI Trevi Therapeutics	7/1/2025	Initiated Coverage	$5.47	$25.00	Overweight
CMPS COMPASS Pathways	6/23/2025	Reiterated Rating	$2.46	$6.00	In-Line
RCKT Rocket Pharmaceuticals	5/16/2025	Boost Price Target	$6.50	$30.00	Overweight
ASND Ascendis Pharma A/S	5/2/2025	Boost Price Target	$177.67	$280.00	Outperform
CGON CG Oncology	4/28/2025	Reiterated Rating	$30.06	$75.00	Overweight
ARTV Artiva Biotherapeutics	3/25/2025	Lower Price Target	$3.92	$20.00	Overweight
AARD Aardvark Therapeutics	3/10/2025	Initiated Coverage	$10.13	$50.00	Overweight
BBIO BridgeBio Pharma	2/21/2025	Reiterated Rating	$37.07	$95.00	Overweight
KRYS Krystal Biotech	2/20/2025	Reiterated Rating	$187.60	$215.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.